Selected Publications
Selected publications in reverse chronological order. Read a full list of publications here.
Kayser, R.R., Arbuckle, M., Simpson, H. B. (2022). Pipeline in Jeopardy – Challenges in Developing Patient-Oriented Interventions Researchers in Psychiatry and Opportunities for Action. JAMA Psychiatry 79 (2): 95-96.
Hezel, D. M.*, Rapp, A. M.*, Wheaton, M. G., Kayser, R. R., Rose, S. V., Messner, G. R., ... & Simpson, H. B. (2022). Resilience predicts positive mental health outcomes during the COVID-19 pandemic in New Yorkers with and without obsessive-compulsive disorder. Journal of Psychiatric Research, 150, 165-172.
Hezel, D. M., Rapp, A. M., Glasgow, S., Cridland, G., & Simpson, H. B. (2022). Year of Zoom in a Year of Doom: Lessons Learned Delivering ERP Remotely During the COVID-19 Pandemic. Cognitive and Behavioral Practice.
Foa, E.B., Simpson, H. B., Gallagher, T., Wheaton, M.G., Gershkovich, M., Schmidt, A… & Rosenfield, D. (2022). Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical Trial. JAMA Psychiatry 79(3): 193-200.
Kayser RR, Senter MS, Tobet R, Raskin M, Patel S, Simpson HB: Patterns of cannabis use among individuals with obsessive-compulsive disorder: Results from an internet survey. Journal of Obsessive-Compulsive and Related Disorder 2021. Full text here.
Patel SR, Gershkovich M, Hinds M, Jankowski S, Dixon LB, Myers RW, Simpson HB: Open forum: A statewide workforce development program to improve care for obsessive-compulsive disorder. Psychiatric Services 2021. Full text here.
Simpson HB, Foa EB, Wheaton MG, Gallagher T, Gershkovich M, Schmidt AB, Huppert JD, Campeas RB, Imms PA, Cahill SP, DiChiara C, Tsao SD, Puliafico AC, Chazin D, Asnaani A, Moore K, Tyler J, Steinman SA, Sanchez-LaCay A, Capaldi S, Snorrason I, Turk-Karan E, Vermes D, Kalanthroff E, Pinto A, Hahn C, Xu B, Van Meter PE, Katechis M, Scodes J, Wang Y: Maximizing remission from cognitive-behavioral therapy in medicated adults with obsessive-compulsive disorder. Behavior Research and Therapy 2021. Full text here.
Kayser RR, Gershkovich M, Patel S, Simpson HB: Integrating videoconferencing into treatment for obsessive-compulsive disorder: Practical strategies with case examples. Psychiatric Services 2021. Full text here.
The ENIGMA-OCD Working Group (of which Dr. Helen Blair Simpson is a member): Mapping cortical and subcortical asymmetry in obsessive-compulsive disorder: Findings from the ENIGMA consortium. Biological Psychiatry 2020 (in press) Full text here.
Simpson HB, van den Heuvel OA, Miguel EC, Reddy YC, Stein DJ, Lewis-Fernández R, Shavitt RG, Lochner C, Pouwels PJW, Narayanawamy JC, Venkatasubramanian G, Hezel DM et al. Toward identifying reproducible brain signatures of obsessive-compulsive profiles. BMC Psychiatry 2020; 20(68) Full text here.
The ENIGMA-OCD Working Group (of which Dr. Helen Blair Simpson is a member): Intra-individual brain structural covariance networks in obsessive-compulsive disorder: A graph analysis from the ENIGMA Consortium. Brain 2020; 143(2): 684-700 Full text here.
Kayser RR, Raskin M, Snorrason I, Hezel DM, Haney M, Simpson HB: Cannabinoid augmentation of exposure-based psychotherapy for obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 2020; 40(2):207-210 PMID: 32068563
Stein D, van den Heuvel O, Lochner C, Miguel E, Shavitt R, Costa D, Reddy J, Simpson HB: Obsessive-compulsive disorder. Nature Reviews Disease Primers 2019; 5(52): 1-21 Full text here.
Kayser RR, Snorrason I, Haney M, Lee FS, Simpson HB: The endocannabinoid system: a new treatment target for obsessive-compulsive disorder? Cannabis and Cannabinoid Research 2019; 4(2):1-11 Full text here.
Foa EB, Simpson HB, Rosenfield D, Liebowitz MR, Cahill S, Huppert JD, Bender J, McLean CP, Maher MJ, Campeas R, Hahn C, Imms P, Pinto A, Powers MB, Rodriguez CI, Van Meeter PE, Vermes D, Williams MT: Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and ritual prevention or risperidone in adults with obsessive-compulsive disorder. The Journal of Clinical Psychiatry 2015; 76(4): 440-446 PMID: 25375780 PMCID: PMC4524354 Full text here.
Marsh R, Horga G, Parashar N, Wang Z, Peterson BS, Simpson HB: Altered activation in fronto-striatal circuits during the sequential processing of conflict in unmedicated adults with obsessive-compulsive disorder. Biological Psychiatry 2014; 75(8): 615-622 PMID: 23489416 PMCID: PMC3722261 Full text here.
Posner J, Marsh R, Maia TV, Peterson BS, Gruber A, Simpson HB: Reduced functional connectivity within the limbic cortico-striato-thalamo-cortical loop in unmedicated adults with obsessive-compulsive disorder. Human Brain Mapping 2014; 35(6): 2852-2860 PMID: 24123377 PMCID: PMC4142493 Full text here.
Rodriguez CI, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D, Flood P, Simpson HB: Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: Proof-of-concept. Neuropsychopharmacology 2013; 38(12): 2475-2483 PMID: 23783065 PMCID: PMC3799067 [This won the Neator Award for best paper in Neuropsychopharmacology in 2013.] Full text here.
Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J, Marcus SM, Williams MT, Waver J, Vermes D, van Meter PE, Rodriguez CI, Powers M, Pinto A, Imms P, Hahn C, Campeas R: Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: A randomized clinical trial. JAMA Psychiatry 2013; 70(11): 1190-1199 PMID: 24026523 PMCID: PMC3955365 Full text here.
Foa EB, Simpson HB, Liebowitz MR, Powers MB, Rosenfield D, Cahill S, Campeas R, Franklin M, Hahn C, Hembree EA, Huppert JD, Schmidt AB, Vermes D, Williams MT: Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder. The Journal of Clinical Psychiatry 2013; 74(5): 464-469 PMID: 23759449 PMCID: PMC3977336 Full text here.
Rodriquez CI, Bender J, Rynn M, Snape M, Simpson HB: Minocycline augmentation of pharmacotherapy in OCD: An open-label trial. The Journal of Clinical Psychiatry 2010; 71(9): 1247-1249 PMID: 20923629 PMCID: PMC3923525 Full text here.
Maher M, Huppert JD, Chen H, Duan N, Foa EB, Liebowitz MR, Simpson HB: Moderators and predictors of response to cognitive-behavioral therapy augmentation of pharmacotherapy in obsessive-compulsive disorder. Psychological Medicine 2010; 40(12): 2013-2023 PMID: 20416137 PMCID: PMC3953340 Full text here.
Simpson HB, Foa EB, Liebowitz MR, Ledley DR, Huppert JD, Cahill S, Vermes D, Schmidt AB, Hembree E, Franklin M, Campeas R, Hahn C-G, Petkova E: A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. American Journal of Psychiatry 2008; 165(5): 621-630 PMID: 18316422 PMCID: PMC3945728 Full text here.
Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, Huppert JD, Kjernisted K, Rowan V, Schmidt AB, Simpson HB, Tu X: Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. American Journal of Psychiatry 2005; 162(1): 151-161 PMID: 15625214 Full text here.